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Abstract 
We integrate insights from open innovation and collaborative strategic foresight (CSF) to 
theorise collaborative innovation practice. Adopting a case-based approach, we draw 
qualitative insights from two Chinese pharmaceutical firms - one private and one state-owned, 
both engaged in new product development (NPD) projects. Focusing on how firms leverage 
CSF to support their NPD, we offer an interpretive account of how the two firms take 
different approaches to orchestrating their strategic partnerships to identify, explore and 
exploit opportunities for innovation. Our study sheds light on how focal firms, through SF 
practices of perceiving, prospecting, and probing, translate ideas and insights gained from 
collaborating partners into action to support their innovation processes. Expanding and 
shifting the focus of traditional strategic foresight from an inward-looking orientation to an 
outward-looking CSF, we show how focal firms could tap into distributed knowledge 
embedded in sources located beyond the theoretical boundaries of the firm. We argue that 
appropriately managed CSF at different stages of NPD could help companies to better sense, 
seize and integrate potentialities and limits otherwise overlooked by their competitors. We 
reveal that the type of ownership, an unexplored factor, explains a firm’s different CSF 
approaches (explorative vs exploitative) in innovation for NPD.  
Keywords: Collaborative strategic foresight, open innovation, new product development, 
Chinese pharmaceutical firms
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1. Introduction
Strategic foresight (SF), as an organisational capability for exploring and exploiting limits and 
potentialities otherwise overlooked by competitors, has come to dominate contemporary 
discourse on successful open innovation for new product development (NPD) (Andersen and 
Andersen, 2014; Gordon et al., 2020; Lee et al, 2019; Zhu et al., 2019). In practice, many 
firms have responded to calls for better integration of SF in the open innovation process 
(Korreck, 2018; Rohrbeck and Gemünden, 2011) by adopting forward-looking practices – to 
help them manage the fleeting context in which they conceive, create and capture sustainable 
value from their innovation (Rohrbeck and Kum, 2018; Schwarz et al., 2019). Recognising 
the high stakes involved, firms now devote considerable effort to developing what has come 
to be known as collaborative strategic foresight (CSF): SF that goes beyond the theoretical 
boundaries of the firm, building on partnerships to keep abreast of new innovative practices 
and emerging technological trajectories (Calof et al., 2018; Heger and Boman, 2015). CSF 
expands the boundaries of traditional SF to include leveraging distributed knowledge sources 
through joint discussion and analysis with partners (Gattringer et al., 2017). Yet, as we 
describe later, fundamental questions remain concerning how focal firms employ CSF to 
translate ideas and insights from their collaborative partnership into actions to support their 
innovation processes. The shift from internal-based SF to outward-looking CSF epitomises 
interaction with partners and even competitors in the value network (Fritzsche, 2018; Weiner 
et al., 2019) and has two fundamental implications for theorising CSF in organising for NPD.  
 First, CSF marks a strategic shift from a ‘trend–impact–reaction’ chain to 
‘trend–context (interaction)–strategy' (Daheim and Uerz, 2008, p.335) when identifying 
opportunities for innovation. Interactions with partners as promoted by foresight scholarship 
help firms remedy the fundamental deficiencies associated with their corporate foresight 
exercises (Sarpong and Meissner, 2019), overcome barriers in open innovation (Bogers et al, 
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2018) and challenge firms to ‘think the unthinkable’ in ways that expand the range of 
innovative opportunities (Heger, and Boman, 2015). In this regard, CSF facilitates open 
innovation, by targeting potential partners whose capabilities and visions complement the 
firm's own competences and images of the future (Gattringer et al., 2017; Heger, 2014). Thus, 
CSF practices in organising can enable a faster lead time, contribute to ongoing assessments 
of the novelty, performance and potential market success of new products, in ways that can 
help firms learn and react faster to further market needs (Jissink et al., 2014; Yoon et al., 
2018).  
 Second, CSF is interactive in nature and facilitates the exchange of deep tacit 
knowledge among diverse participants (Weigand, et al., 2013). The collaborative approach, 
with the expanded foresight horizon, provides a context for high-quality foresight activities 
(Heger and Boman, 2015). Insights derived from the interaction trigger the focal firm to 
review its own practices, their underlying assumptions and subsequently to embed the insights 
into future organisational responses and practices (Calof et al., 2018). In other words, CSF 
provides opportunities for firms to assimilate internal and external knowledge as well as their 
integration across organizational boundaries, an ability which is defined as ambidexterity 
(Paliokaite and Pacesa, 2015). An ambidextrous organisation can exploit current market 
opportunities and existing capabilities for short-term firm performance, and explore new 
opportunities to prepare for the future (Mich et al., 2012; Raisch and Zimmermann, 2018); it 
also has combined skills to manage core and non-core businesses (McGrath et al., 2006). 
Furthermore, the focal firm can use different approaches at different points in time to manage 
the paradox of exploration and exploitation (Maclean et al., 2020) while knowing competing 
priorities in innovation enabled by CSF; hence CSF fosters organisational ambidexterity 
(Paliokaite and Pacesa, 2015; Rohrbeck and Gemunden 2011). Overall, CSF has the potential 
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to significantly boost collaborating firms’ innovation output and overall competitiveness (Ehls 
et al., 2016; Pittaway et al., 2004). 
  Although recent research has highlighted how CSF has come to be labelled and identified 
in the context of NPD (see: Weigand et al, 2014; Weiner et al., 2018; Zeng, 2018), empirical 
work exploring how they cumulatively support NPD processes is sparse. However, the 
questions remain concerning how focal firms engage CSF to leverage ideas and insights from 
their collaborative partnership into actions to support their innovation processes. We follow 
Sarpong et al. (2014) in surmising that these questions are often relegated because of the 
“theoretical and methodological complexities involved in mapping the tasks, connections and 
architectures that foresight processes require”.  
  In response to this lacuna, we investigate how firms engage CSF in open innovation 
for NPD, drawing on qualitative evidence from two Chinese pharmaceutical firms: one 
private and one state-owned. We observe that innovation in the Chinese pharmaceutical 
industry, as anywhere else, has long regulatory approval cycles and hence hardly any firms 
are able to single-handedly pursue NPD (Li et al., 2016). This makes an interesting and 
relevant context for comparing and contrasting how firms can employ CSF to leverage 
relevant insights from their collaborating partners to support innovation. We make salient 
contributions to the SF literature: our study posits that the traditional SF boundary should be 
expanded in the NPD context to create value through collaborative partnership. It contributes 
to the understanding of the micro-foundations of SF, by identifying strategic practices 
employed by firms to leverage the ‘know-how’ of partners to support the NPD processes.  
  Specifically, we explore how the collaborative ‘foresightful’ practices through 
perceiving, prospecting and probing, channel more and deeper future insights into actions at 
each stage of NPD to facilitate innovation. Our study has practical implications for how 
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pharmaceutical companies could appropriately manage CSF by dynamically re-defining the 
foresight boundaries at different NPD stages to support innovation.   
2. Theoretical Background
2.1 From strategic foresight to collaborative strategic foresight in open innovation  
The traditional closed model of innovation that relies on in-house idea generation has been 
challenged as a result of knowledge becoming very modular and widely distributed (Calof et 
al., 2018; Fritzsche, 2018). This is especially the case in the pharmaceutical industry, where 
innovation is evolving towards a more network-based and open process (Dong and McCarthy, 
2019; Van der Duin, 2006), in response to technological changes and the ever increasing 
distribution of knowledge. As ‘open innovation’ comes into the scene, many firms actively 
seek information and ideas from actors located beyond their organisational boundaries and 
frequently integrate external partners in their innovation and value-adding activities (Bogers, 
et al., 2019; Ven der Duin et al., 2014). Increasingly, firms need to develop their SF potential 
in order to profit from their open innovation networks (Calof et al., 2018; Nambisan et al., 
2018). By SF, we refer to the creative evaluation and (re)configuration of sources of 
potentialities and limits to future resources and productive outcomes (Chia, 2008; Sarpong 
and Maclean, 2014). As a distributed organising capability, SF enables organisations to detect 
discontinuous change early, interpret the consequences for the firm and formulate effective 
responses, while maintaining a coherent and functional forward-looking view (Rohrbeck and 
Kum, 2018). 
     Prior literature theorises SF as a “refined sensitivity for detecting and disclosing” (Chia, 
2004, p.22) future relevant information which provides opportunities to prepare for several 
possible future scenarios of the business environment (Fergnani, 2020). In this regard, a 
plethora of foresight practices ranging from business war-gaming to counterfactual analysis 
have been deployed at the organisation level (cf. Popper, 2008; Iden et al., 2017; Schwarz et 
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al., 2019). Foresight is not simply to build a tool for the use at a future time, but to bring 
future insights into the present, and bridge goals and the present state with strategies and 
actions (Hines et al., 2017; Gordon, Rohrbeck, Schwarz 2019; Paliokaite and Pacesa, 2015). 
Of particular relevance to our study is the work of Rohrbeck (2010) and Rohrbeck and Kum 
(2018) which identifies three generic strategic foresight practices of perceiving, prospecting 
and probing (3Ps), which firms may employ to organise and translate ideas and insights into 
actions to support their innovation processes. 'Perceiving' refers to the identification and 
analyses of trends and events in the business environment; 'prospecting', akin to sense-making, 
involves the translation of inarticulate or unconscious signals into insights; 'probing' 
encompasses activities aimed at transforming the insight generated through prospecting into 
actions hitherto unthought-of by competitors.  
 While this stream of literature has extended our understanding of the context within 
which strategic foresight is nurtured, the traditional SF approach, focusing on within-firm 
practices, is restricted to internal structures and existing mental models and may result in one 
dimensional narrow-sightedness and strategic myopia (Gattringer et al., 2017; Heger and 
Boman, 2015). In addition, managerial foresight decisions might also be constrained by 
bounded rationality and managerial cognitive limits (e.g. context, mindset, experience and 
time limit in a changing environment) (Mackay and McKiernan, 2004; Shala, 2018). To 
transverse these limitations, many organisations now employ CSF, which prioritises the 
search for ideas and insights located beyond the conventional organisational boundaries. 
Organisations collaborating across boundaries can detect ‘the right’ future developments five 
years ahead of competition, which would not be possible if they had relied on their own 
foresight (Wiener, 2018, p60). CSF fosters ‘outside-the-box thinking’, allowing firms to tap 
into knowledge embedded in the context beyond their immediate value network or domain of 
existing operations (Gattringer et al., 2017; Van der Duin et al., 2014).  
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   Emphasising the shift to CSF as a distributive capacity, the emerging literature 
recognises the link between CSF and open innovation: both are externally oriented, share 
techniques and methodologies which, when taken together, can be of enormous value to 
innovation performance (Calof et al., 2018; Heger and Rohrbeck, 2012). In this regard, CSF 
strengthens innovation partners’ potential to explore emerging technologies, disrupt existing 
technological trajectories and develop products of the future. Thus, while open innovation 
drives the processing of often disparate and complicated information collected from both 
internal and external networks, CSF prioritises the integration of the processed information 
into meaningful, future-oriented knowledge. Thus, CSF helps validate, refine and prioritise 
ideas and exploit them towards an idealised future vision (Calof et al., 2018). From this 
perspective, we argue that it is imperative to integrate CSF in each stage of the NPD process: 
discovery, development and commercialisation. However, the question is: how do focal firms 
explore and exploit CSF to leverage relevant insights from their collaborating partners to 
support innovation at each stage of the NPD process? Below, we draw on the 3Ps (Rohrbeck, 
2010; Rohrbeck and Kum, 2018) to delineate how CSF comes to be identified in the context 
of NPD in pharmaceutical firms. 
2.2 Incorporating the foresight practices of perceiving, prospecting and probing in open 
innovation 
Inspired by Choo’s (1996) ‘knowing organisation’ principle (organisations use information to 
construct meaning, create knowledge and make decisions) and Daft and Weick’s (1984) 
model of organisations as interpretative systems, Rohrbeck and Kum (2018) propose a 
foresight framework - perceiving, prospecting, and probing (3Ps). The 3Ps reflect the similar 
terrain of the six steps defined by Hines et al (2017) in achieving SF competence (framing, 
scanning, futuring, visioning, designing, adapting), but goes one step further by extending it 
with particular attention to the phase of probing (Gordon et al., 2019). The 3Ps are 
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interconnected and observable practices (Rohrbeck and Ram, 2019) which enable us to 
capture and examine how SF supports the stages of NPD in pharmaceutical firms.   
2.2.1 Perceiving idea identification at the discovery stage 
The early stage of NPD in the pharmaceutical industry is characterised by high uncertainty 
and high failure rates because little information is available and predictions are not very 
accurate (van der Duin and Hartigh, 2009). Firms' priority at this stage is to explore new 
product ideas (see Figure 1). SF-perceiving practices are aimed at identifying and linking 
embodied know-how and capabilities to innovation opportunities (Jolly, 1997). These 
activities are shaped by market and technological insights, as practised by the focal firm and 
its partners (Rohrbeck and Kun, 2018). Activities that engage external experts through 
brainstorming, expert panels or future workshops/conferences can help reduce blind spots in 
the focal firm’s peripheral vision (Hojland and Rohrbeck, 2018; Shoemaker, 2019). The result 
of the perceiving practices is the sensing and identification of what can be described as weak 
and strong signals of change, ahead of the competition (Jissink et al., 2014; Rohrbeck and 
Kum, 2018). This may involve the leveraging of the embodied knowledge of the innovation 
network, orchestrated by the focal firm to improve its understanding of the ‘product concept’ 
which involves the integration of both technologies and the user’s performance expectations. 
Overall, perceiving practices play an initiator role in innovation, triggering new insights, 
concepts and idea propositions (Rohrbeck and Gemunden, 2011).  
2.2.2 Prospecting potentialities and limits at the development stage  
Prospecting kicks in during the development stage of NPD, translating signals into insights 
though a process of sense-making, which involves the interpretation of the received signals 
and their consequences for the yet-to-be-realised innovation (Gavetti and Menon, 2016; 
Paliokaite and Pacesa, 2015; Rohrbeck and Kum, 2018). Prospecting enables the focal firm to 
gain deep and reinforced understanding of the yet-to-be-realised innovation. The tipping point 
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is the moment when the focal firm can foresee a product that could overcome real or 
perceived technology and market barriers (Hojland and Rohrbeck, 2018). The gained insight 
may allow the focal firm to identify alternative pathways and superior courses of action that 
are likely to allow it to create and capture sustainable value from the yet-to-be-realised 
innovation (Rohrbeck and Kum, 2018; Sarpong and Maclean, 2012). Thus, prospecting tends 
to use more structured, future-oriented techniques, such as value chain analysis, case 
probabilities and impact simulations (Sarpong and Maclean, 2014; Popper, 2008). By gaining 
more knowledge about the consequences of a choice, the focal firm may be able to identify 
viable responses to challenges arising from the NPD process. We surmise that both perceiving 
and prospecting fall into the domain of forward-looking cognitive search and can uncover 
both local and distant alternatives (Gavetti and Lvinthal, 2000). Alternatives are evaluated 
based on the actor’s incomplete mental model of the world and built on the accumulated tacit 
knowledge (Hojland and Rohrbeck, 2018). 
2.2.3 Probing at the commercialisation and production stage 
While prospecting practices offer insights into the future of the yet-to-be-realised innovation, 
probing activities specifically aim to translate the garnered insights into actions (Costanzo, 
2004; Hojland and Rohrbeck, 2018). Probing, therefore, 'triggers meaningful organisational 
responses to change' (Hojland and Rohrbeck, 2018, p. 735) and legitimises the search for 
alternative courses of action (Rohrbeck and Kum, 2018, p. 107). Probing practices typically 
move from 'cognitive search' (perceiving and prospecting) to 'experimental search’ (Gavetti 
and Levinthal, 2000). It focuses the ‘mind’ of the focal firm on finding solutions to perceived 
and anticipated problems that have the potential to derail the technology-market coupling 
process (Gavetti and Menon, 2016). Thus, the practice of probing relies exclusively on trial 
and error experiments (Gavetti and Rivkin, 2007). Examples of activities underpinning 
probing may include the establishment of living labs, where experiments are brought out of 
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the focal firm’s R&D (Research & Development) departments to real life environments with 
the participation of users and network partners (Fritzche, 2018; Kim et al., 2019).  
     To conclude, SF, manifested in a set of practices of perceiving, prospecting and probing, 
helps organisations benefit from both cognitive (perceiving, prospecting) and experimental 
(probing) searches (Hojland and Rohrbeck, 2018). However, these practices rarely engage 
with external actors (e.g. Rohrbeck and Kumd, 2018). The only exceptions are the incidental 
findings of Hojland and Rohrbeck (2018) showing that partnership can bring significant 
insights into the prospecting practice in exploring new markets, and those of Costanzo (2004) 
demonstrating that probing through partnership reveals opportunities that would not have 
otherwise been identified. SF practices help build organisation’s core dynamic capabilities – 
sensing, seizing, and recombination and reconfiguration (Schwarz, Rohrbeck, and Wach, 
2018; Teece, 2017). Scanning and interpretative activities refer to ‘sensing’, acting upon it 
helps ‘seizing’ opportunities (Teece, 2007). Studies mix the 3Ps together, and found SF 
practices mainly contribute to sensing activities and to a lesser extent on nurturing the seizing 
capability or activity initiation (Heger and Boman, 2015; Gattringer et al., 2017; Rhisiart et al., 
2015; Schwar, Rohrbeck, Wach, 2018). While SF is seen as the microfoundation of dynamic 
capabilities, our understanding of how the 3P practices are employed and manifested in 
building dynamic capabilities is incomplete. Particularly, there is a lack of empirical research 
into how SF should be expanded in the NPD context to leverage insights from collaborating 
partners through perceiving, prospecting and probing.   
--- Insert Figure 1 here --- 
3. Research Methods
We develop our contribution in the context of the Chinese pharmaceutical firms because they 
face intensive competition in NPD subsequent to significant regulatory changes in accordance 
with China’s economic reform. On 1st January 1993, the major amendments to the Patent 
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Law came into effect in China, marking a historical transformation for the Chinese 
pharmaceutical industry (SIPO, 2011). The amendments stipulated that pharmaceutical 
products, methods and usage can all be patented, endowing inventors with true rights (Hill 
and Judith, 1993; Okadal And Nagaoka, 2017). This meant that Chinese pharmaceutical firms 
could no longer copy drug formulas patented by foreign companies after 1993. This motivated 
Chinese pharmaceutical firms to pursue alternative pathways to business development: to 
manufacture generic drugs once the foreign firms’ patents expire; to purchase the intellectual 
property rights of a patent drug (with extremely high costs); or to invest in developing 
innovative drugs (Cao, 2004).   
Drug development in China follows a four-phase process similar to that in the Western 
countries: laboratory test (Phase I), animal test (Phase II), clinical trials (Phase III) and post 
marketing surveillance (Phase IV) (SFDA, 2005; Dimasi et al., 2003; CDER, 1998; FDA, 
1998). The four phases involve a complex and volatile process requiring collaboration with 
external partners and ushered in a highly developed foresight capability for firms to navigate. 
The complicated nature of the NPD process, therefore, places concurrent demands on pharma 
firms to leverage different SF approaches at different stages of NPD, enabling firms to create 
and capture value from NPD.  
3.1 Case selection  
We employed a qualitative case study research strategy (Yin, 2009) to allow us to focus on 
our key objective - to investigate how Chinese pharmaceutical firms leverage CSF at each 
stage of NPD. Specifically, we focused on the NPD processes of two firms - one privately 
owned and the other state-owned. Both firms are located in Beijing where there is a density of 
high-tech firms (Yam et al., 2004). A two-case approach selected in the same industry allows 
more powerful analytical conclusions to emerge from each of the two cases than from a single 
case study alone (Yin, 2009). 
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  We adopted Buck’s (2011) guidance for case selection by employing a two-stage 
approach in selecting the case organisations (Buck, 2011; Eisenhardt, 1989). First, we started 
with an informal sampling selection with broad selection criteria: high-tech enterprises 
operating in the pharmaceutical industry located in Beijing. We then applied the following 
criteria to screen firms in the first stage: (a) to focus on firms that are active in NPD, so firms 
which only produce generic drugs or traditional Chinese medicine are excluded; (b) as a 
complete NPD process in the pharmaceutical industry takes a long time (PhRMA, 2013), 
firms included in this study must have been in operation for at least 10 years. Based on the 
above criteria, we approached firms recommended by personal contacts and by cold calls, 
resulting initially in four selected firms.  
  We then applied theoretical sampling and identified two firms (Statepharma and 
Privatepharma) from the four initial cases, based on theoretical reasons (Eisenhardt, 1989). 
First, while collaboration with other firms was found in all four initial cases, in order to 
explore in-depth insights in the leveraging of CSF in innovation, we selected cases with a 
minimum of two or more collaborative arrangements with external partners aimed at 
improving the NPD processes. Second, as this study aims to reveal the pattern of CSF 
activities reflected in each stage of NPD, we chose two firms from the same pharmaceutical 
industry to hold industry constant. Third, the choice of a state-owned firm (Statepharma) and 
a private enterprise (Privatepharma) helped compare, contrast and control the impact of 
governance and ownership structure of a firm on its choices of CSF practices and the kind of 
activities they engaged in. The different governance structures in state-owned and private 
enterprises provided contrasting insights into endowed resources and organisational context, 
elucidating the underpinning logic of the choice of CSF approaches in NPD. Finally, both 
firms invested in NPD intensively. Statepharma developed more than 10 patented products 
and Privatepharma had two patented products. Moreover, the two firms selected were willing 
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to take part and hence our continued access was granted. Therefore, our two cases - one 
state-owned and one private, in the same industry and the same city, were purposely chosen to 
reduce extraneous variation and focus on our research objective (Eisenhardt, 1989; Pettigrew, 
1988). 
Case 1. Statepharma  
Statepharma was one of the top five pharmaceutical firms in China in terms of investment in 
NPD. Originating as a military medical centre in 1937, Statepharma became a state-owned 
pharmaceutical company in 1954 and was publicly listed in 1997. Located in Beijing and 
neighbouring universities and research institutes, it capitalised on the location to access 
research resources, outputs and advanced knowledge related to NPD. Statepharma focused on 
the 'development' of drugs, that is, converting semi-finished new products into marketable 
products. Its own research centre served product development for all its subsidiary 
manufacturers, covering three key product lines: large infusion, cardiovascular medicine and 
hypoglycaemic medicine. The research centre’s key responsibility was to provide 
market-ready drugs for the subsidiaries. The speed of commercialisation of new drugs was 
vital for its survival.  
Case 2. Privatepharma 
Privatepharma was a leading firm in Hepatitis B research in China. Unlike Statepharma, 
Privatepharma focused on 'research' into new drugs, providing liver disease diagnosis and 
treatments. Founded in 1994, Privatepharma was a private enterprise located in Beijing. The 
Founder was an expert in infectious disease, being the first person in China to propose 
immunotherapy, marking a departure from the universal but less effective treatment for liver 
disease. The Founder developed a new diagnosis method and personalised treatment, targeting 
patients on whom conventional treatment was ineffective. Privatepharma’s first patent was a 
new therapy, including two drugs and a vaccine for Hepatitis B. Privatepharma experienced a 
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very difficult start-up period and even rented labs to do experiments. After more than ten 
years’ development, Privatepharma built its own research labs and moved from outsourcing 
research to in-house R&D.  
3.2 Data collection 
Data for our empirical inquiry were collected chiefly through semi-structured interviews with 
NPD managers and team members in 2008 and 2009. Data were then kept up to date with the 
recent NPD development of the two firms until the end of 2015 based on secondary data (e.g. 
the company websites, annual reports and other trade publications). To collect in-depth data, 
we used purposive sampling (Lincoln and Guba, 1985) to identify key informants who were 
most knowledgeable about NPD (Saunders et al., 2009). Informants selected covered the key 
roles in the R&D Department (Privatepharma) and the Research Centre (Statepharma):  the 
heart of NPD within the two case study firms. In Privatepharma, the R&D Manager had 
worked there since its inception. In Statepharma, the Manager of Administration responsible 
for co-ordinating all the NPD activities internally and externally at the Research Centre had 
worked for the firm for about 16 years and the Manager of Information Management, 
responsible for evaluating NPD projects, had worked at Statepharma for 14 years. We also 
selected other key persons who had knowledge about the NPD and management, such as the 
General Manager, the Founder and the Manager of Production.  
   In total, we conducted eight interviews (five with Privatepharma, and three with 
Statepharma) over a one-year period. All interviews were conducted by the authors 
face-to-face on the respective sites of the firms. Once we had conducted five interviews with 
Privatepharma and three interviews with Statepharma, additional insights from further 
interviews were marginal, indicating a point of diminishing returns (Strauss and Corbin, 
1998). This indicated that the number of interviews conducted in each firm was sufficient to 
reveal the NPD process. Therefore, interviews were stopped at this point when incremental 
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learning was minimal and no further considerable insights were gained; theoretical saturation 
was reached (Eisenhardt, 1989).  
  The interviews were semi-structured and interview questions covered four broad 
dimensions: a. strategic objectives of NPD and the necessity of involving external partners; b. 
the use of CSF: the collaborative partner, their inputs, the CSF methods, the CSF practices 
and activities in the daily operation, how they are different at each stages of NPD; c. the value 
of CSF: the course of action taken, the value of CSF in NPD and the consequences; and d). 
the rationales behind decisions about selecting the forms of collaboration at different NPD 
stages. Each interview lasted from one to one and a half hours. All the interviews were 
recorded and transcribed for data coding and analysis. Where available, we supplemented our 
interview data with secondary data, such as information on company websites. The data 
collected from different informants and alternative sources were triangulated (Flick, 2018), 
before we began the analysis to identify viable theoretical explanations. 
3.3 Data analysis 
Following Eisenhardt's (1989) recommendation for analysing case study data, we adopted 
three key steps in order to understand how firms leverage CSF in the NPD process. First, we 
conducted within-case analysis, by drawing a timeline of four key stages of NPD and then 
zoomed into each stage to identify CSF practices and activities employed to conduct NPD. 
Second, we conducted cross-case analysis to compare not only similarities, but also 
differences between the two cases, in order to capture the interaction between the firms and 
their collaborative partners in NPD, the nature CSF and to understand the dynamics involved 
in firms’ choice of forms of collaboration. Third, we incorporated the themes emerging from 
the cross-case analysis into a theory of CSF in managing NPD. In particular, we identified 
three CSF approaches managing different stages of NPD: loosely defined friendship/network, 
contract-based and lead-operator, as summarised in Tables 1, 2 and 3.  
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--- Insert Tables 1, 2 and 3 here --- 
4. Research Findings
Our findings suggest that both private and state-owned Chinese ‘pharma’ (pharmaceutical) 
firms engaged foresight in collaborations with other organisations at each stage of the NPD 
process (an open rather than closed innovation). While both firms extended the boundary of 
foresight to involve collaborative partners through perceiving, prospecting and probing to 
support innovation, the state-owned firm, although endowed with slack resources, was much 
more prone to an exploitative, or what we refer to as a ‘D (development)-focused’ approach. 
This was because its government-assigned CEOs were on fixed-term contracts and hence 
fixated on short-term outcomes. In contrast, the private firm, despite being 
resource-constrained, was proactive in tapping into distributed expertise beyond the firm’s 
boundaries, reflecting an explorative or ‘R (research)-focused’ NPD strategy.  
4.1 Perceiving in Stages I and II  
Both the private and state-owned pharmas proactively monitored changes in the external 
environment for new product ideas in Stages I and II. They predominantly did this through the 
exploration and exploitation of knowledge and information embedded in the established 
personal networks of the managers, founders and research employees. Thus, CSF practices at 
this stage were conducted through informal and ad-hoc collaborative partnership with external 
experts through workshops and conferences, group discussions and so on. While 
Privatepharma focused on monitoring the fast evolution of the new technologies for liver 
diseases, Statepharma prioritised the gathering of information on semi-finished innovation 
outcomes with the most market potential to refine and upgrade their key product lines. The 
key founder of Privatepharma, a renowned doctor specialising in Hepatitis B in China, quit 
his job in a state-owned hospital, where he led national key research projects and received 
special contribution awards. He always kept himself at the forefront technology through 
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networking among the wider expert community. Such informal ways of interacting with 
doctors and scientists at research institutes and hospitals provided Privatepharma with the 
flexibility to explore the future changes earlier than competitors. The founder understood that 
there was a great number of Hepatitis B patients in China and that the method developed in 
the Western countries (using antiviral drugs to cure HBV) was not effective for all patients. 
The initial idea of developing technologies and treatment to improve Hepatitis B patients' 
immune systems was derived from his continuous communication with doctors and scientists 
about the development in the field (external exploration) together with his experience and his 
accumulated expert knowledge (internal exploration). Indeed, the external knowledge 
exploration exposed the innovation team at Privatepharma to increased possibilities of 
accessing world-leading technologies, that had the potential to open up new opportunities.  
  'During the coffee break (at the international conference in the US), a leading professor, 
James Sheffield (pseudonym), who developed the world's first medicine - 'white 
cellhormone 2' for improving cancer patients' immune system- approached me. He is very 
interested in my presentation and asked me, 'my new drug might work better than yours 
on HBV, why don't you do research into it?' I said, 'I did not know, if I knew, I would do it'. 
He encouraged me to do the test and generously gave me 10 bottles to bring back to 
China (worth $50,000 in 1983).' 
While Privatepharma proactively engaged in diverse perceiving activities with national 
and international experts to keep abreast of cutting-edge technology in the field (exploring for 
long-term R-capability development), Statepharma exploited its collaborative partners' 
knowledge and expertise for information on chemical compounds with the most commercial 
potential (for short-term profit maximisation, to enhance D-capability). 
'One of our colleagues heard from his friend, who is a research expert, that an 
anti-hypertensive formula - Number zero- being developed (close to finish of Phases I 
and II) by an expert in an institute in Shandong, had a high market potential if successful. 
But that expert did not have resources to carry on clinical trials (Phase III). We then 
approached this expert quickly and purchased this semi-finished product (Manager of 
Information Dept., Statepharma).'  
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Here, foresight exercises conducted with external experts through informal partnership 
kept both firms constantly informed of diverse, reliable and critical NPD information at not 
only the research forefront, but also the market forefront. 
'They are practising doctors, they know new product gaps, supply and demand gaps of 
certain products. The insights gained from the continuous interaction with them prompted 
us to define our innovation around three key areas in China: large infusion, 
cardiovascular medicine and hypoglycaemic agents. (Manager of Information Dept., 
Statepharma).'  
'Involving these friendship-based relations in our foresight activities for NPD is critical 
because they are the origin of innovation, the collaboration with these experts both at 
home and abroad kept our research cutting-edge, not in a closed way (Founder, 
Privatepharma).'  
Although the external experts were loosely defined and no contracts were found to 
specify their responsibilities and roles, they formed as an 'ad-hoc advisory board' to provide 
insights for future innovation and the manager of Privatepharma named them 'an extended 
R&D function of the firm'.   
4.2 Prospecting and probing in Stage III 
Once a signal of a likely future new product idea was perceived, both firms investigated the 
viability of the innovation opportunity by exploring more structured CSF practices with 
experts in hospitals and research institutes. The focus of innovation at this stage was to 
transform the new product idea developed in the pre-clinical phase (Stages I and II) into a 
usable drug through clinical trials. The boundary of foresight practices was refined. The 
unstructured informal knowledge exchange through loosely defined personal networks was 
replaced with a more structured governance form with clearly defined processes and rules in a 
long-term, agreement-based collaboration. Privatepharma prospected alternative treatment 
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methods for Hepatitis B, inspired by the exploration of several joint experiments with external 
experts: one was an antiviral drug (the first generation of antiviral drugs for liver disease, at 
Guangdong Research Center, China); the other two focused on drugs for improving patients’ 
immune systems: Thymosin (collaborated with several leading experts: a biochemist from the 
Chinese Academy of Medical Sciences, a biologist from Peking University, and another 
biochemist from Nanjing University) and 'White Cell Hormone 2' (conducted at Qinhuangdao 
Immunology Research Centre, China with samples provided by James Sheffield, from the 
US).  
  CSF activities in joint research reinforced both firms' understanding of the alternatives. 
Insights were gained not only from the interaction of partners with different perspectives, but 
also through the trial-and-error processes. The collaborative insight indicated that screening 
out the right patients was critical, as the same drug was not effective for all Hepatitis B 
patients. This reinforced understanding by prospecting different alternatives and triggered a 
new round of probing for Privatepharma, to develop a diagnostic kit followed by different 
types of treatment with the three optional drugs. One of the diagnostic technologies included 
in the kit was screening, which could help analyse patients' genetic types and find out which 
group of patients was suitable to receive either immune system treatment or antiviral drugs. 
This diagnostic kit could be used in a variety of industries, e.g. hotels, restaurants, massage 
parlours, karaoke bars where business must follow strict health checks for infectious diseases. 
This market potential of the diagnostic technology provided Privatepharma a viable business 
opportunity.  
 The intensive interaction with complementary knowledge, new resources, new 
perspectives and new ways to solve problems not only challenged the mindset of researchers 
from both Privatepharma and Statepharma but also stimulated them to review their own 
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practices through learning by doing. Hence, prospecting and probing practices co-existed at 
this stage of innovation.   
'During the clinical trials (drawing on a cancer treatment in the West using thymus 
hormone extracted from cows to test and treat Hepatitis B patients), in order to solve the 
problem of the shortage of cows in China when preparing for the future long-term supply 
of the new drug, foresight meetings with doctors suggested several alternatives but 
helped us select pigs to replace cows in order to extract thymus hormone. It worked 
effectively, particularly for HBV patients with serious infections. This insight, contributed 
by experienced cancer experts, speeded up our NPD proces, and we became the first to 
use thymus hormone extracted from pigs to improve the immune systems of Hepatitis B 
patients in China (Founder of Privatepharma).’ 
   Statepharma's understanding of the anti-hypertensive drug Number Zero was reinforced 
by the real-time insight gained in experiments.  
'While we collaborated with hospitals doctors on the experiments with the 
anti-hypertensive drug Number Zero, we tested several times and the required 
effectiveness was still not achieved. Based on their experience and expertise, the doctors 
suggested that a change of dose would work. Together we worked on adjustment of the 
dose and eventually made one pill per day sufficient to keep the blood pressure stable' 
(Manager of the Administrative Dept., Statepharma).  
4.3 Probing in Stage IV 
The focus of the innovation shifted from developing new products to commercialisation and 
protection. The new drug gained further approval through experiments with larger populations 
and prepared for mass production. Both firms probed further through partnerships not only 
with experts and doctors in the field, but other organisations embedded in their value 
networks, such as manufactures and sub-contractors. Foresight boundaries were refined again, 
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and foresight generation was achieved through collaborating with carefully selected partners 
while both long-term and one-off contract-based collaboration also took place. Probing for the 
further improvement of the new drug through experimentation helped both firms to maintain 
open access to critical on-site data, through which the firms gained insights via interactive 
learning.  
'Our best-selling anti-hypertensive drug Number Zero underwent the 2nd round of 
innovation, as its side effects needed further investigation. External experts in chemistry 
and pharmacy and hospital doctors were all involved in analysing the causes of the side 
effects and in finding alternative solutions. The insights from the expert panel showed 
that refining and purifying one of the chemicals could reduce the side effects. The 
experiment challenged our original methodology and we had to adjust our operational 
procedure.  We then conducted the fourth phase of clinical trials by collaborating with 
hospitals again and observed the differences.' (Manager of Information Department, 
Privatepharma).  
 CSF probing practices allowed both firms to make timely adjustments and fed 
discoveries at operational level directly back into the two pharmas' on-going R&D. It also 
ensured the use of state-of-art technology and reinforced the understanding of the market. For 
example, the collaborative foresight partners formed an intelligent network to encourage 
divergent thinking. While looking at Number Zero’s future market together with external 
experts and sub-contractors, Statepharma interpreted that there should be a great demand for 
affordable anti-hypertensive drugs in rural areas in China. This insight informed Statepharma 
to create a tailored product profitably by lowering production costs on Number Zero, as well 
as informing future new anti-hypertensive drugs.  
Privatepharma probed through joint experiments with doctors in hospitals on the 
diagnostic kit. Probing practices through intensive interaction with doctors on trial-and-error 
This article has been accepted for publication in a future issue of this journal, but has not been fully edited. Content may change 
prior to final publication. Citation information: DOI10.1109/TEM.2020.3040041, IEEE Transactions on Engineering Management    
22 
experiments formed a rich learning process. Privatepharma brought the problems and 
solutions back and forth many times and reflected on the insights in operations in order to get 
the concept proven in experiments. The collaborative probing catalysed the innovation 
process and the diagnostic kit went through official approval and became Privatepharma’s 
first patented product. Comparatively, insights gained through exploiting international 
knowledge sources through partnership informed Statepharma to license in semi-finished 
projects from other countries, such as Germany, even at the stage of Phase IV, in order to 
commercialise them quickly in China. 
     At the same time, Privatepharma used collaborative insights to exploit in-house 
research capability to source in profitable non-core new products (e.g. cosmetics) in order to 
generate extra income for reinvestment in the core research (triple trajectory: in-house 
production, outsourcing, and source-in non-core research). The exploitation of developed in-house 
research capabilities and the exploration of collaborative resources in innovation across 
different industries helped Privatepharma frame possible future scenarios in the 
bio-technology field. 
With a more stable drug and on-site data, both firms prototyped the production to go 
through official approval, in order to get a certificate that granted the new drug market access. 
The interactions with external experts helped both firms to validate their decisions about what 
should be kept in-house, and what should be outsourced at this stage. 
'We think that we need to recruit expert people and invest in new equipment in 
manufacturing this part of the product, but insights gained from our collaboration 
signaled that this investment might not be used in the future after the completion of 
manufacturing this product, we then adjusted our decision. We sought to co-operate with 
others who are experienced in doing that with higher efficiency and lower costs than us, 
rather than investing in too much now, being locked in missing future opportunities’ 
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(Manager of Information Department, Statepharma). 
    Both firms probed future innovation at this stage through a planned dual trajectory 
approach (in-house and outsourcing), which allowed them to focus on their core competencies 
and, at the same time, recombining and reconfiguring to fully exploit internal and external 
resources and expertise.  
'Following the insights from collaborating with external experts, we sometimes break the 
production of a new drug down into small pieces until making it impossible for others to 
interpret our new innovation, we will ask others to do the most difficult and costly part, 
and then we collect and integrate them to continue the rest of research (Manager of 
Information Dept., Statepharma). 
    The probing practices at this stage were systematic and intelligent. Collectively probing 
the future innovation at this stage informed firms to develop a dual or triple trajectory strategy 
to internalise through ownership in order to protect tacit technological knowledge, 
commercialise the innovation outcome quickly and generate more patents and drugs, hence 
being prepared for future competition. CSF enabled both firms to channel more future insights 
into the front-end of their NPD process. 
5. Discussion
We explored how firms leverage CSF to support open innovation for NPD. Empirically, we 
examined how a private and a state-owned Chinese pharmaceutical firm orchestrated their 
respective NPD partnerships and leveraged others' capabilities and differential images of the 
future to inform innovation activities. We conceptualised CSF as a set of collective practices 
involving external partners to support innovation through identifying new product ideas 
(perceiving), interpreting the consequences of alternatives (prospecting) and actions which 
allow experimenting the value propositions, drug formulations and commercialisation 
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potential (probing). By doing so, our study contributes to the strategic foresight and 
innovation management in several ways. 
     First, our findings reveal that CSF broadens foresight horizon to benefit from 
distributed knowledge sources embedded in inter-firm interactions. Our study responds to the 
call for filling the gap between practice and theory in SF research (see, Iden et al., 2017). It 
looks at practical approaches to SF and revealed how CSF creates value in innovation - a 
missing link in the existing literature. While our findings revealed that incorporating external 
collaborative partners’ inputs in terms of complementary or differing knowledge, information, 
resources, perspectives and ways of doing things into the foresight process not only remedies 
SF's deficiencies, namely its one-dimensionality (Gattringer et al., 2017; Marion et al., 2015), 
but also enhances the effectiveness of SF with richer and broader data than that within 
organisational boundaries in managing innovation process. CSF enabled firms to prioritise 
opportunities in the context of various uncertainties and resource constraints and also to 
respond and act earlier than others (Calof et al., 2018; Jissink et al., 2014). Insights gained 
through on-going interaction with external knowledge sources drove firms constantly to 
renew and re-configure their routines, practices, knowledge bases and structures, in order to 
prepare for future competition. CSF enabled both firms to achieve unforeseen novel 
combinations of knowledge, which could in turn lead to radical and incremental discoveries 
(Ehls, et al., 2016; Pittaway et al., 2004). On the one hand, this supports the participative 
communication point of view of the foresight process (Daheim and Uerz, 2008). On the other 
hand, we go a step further and emphasise that it is the integration of internal and external 
sources where interaction takes place that helps with communication, creates unique 
learning-by-doing opportunities, shares tacit knowledge and generates foresight value.  
     Second, the two firms underwent interactions with the 3Ps (perceiving, prospecting and 
probing) of CSF over the whole innovation process: comparatively, perceiving practices are 
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found appropriate to inform the early stage of NPD (Phase I&II) for sensing distant new 
product ideas; probing at the later stage (Phase IV) for capturing and optimising local 
alternatives; a combination of prospecting and probing at the middle stage of innovation 
(Phase III) for assessing and legitimating alternatives. Here, thoughts trials (prospecting) are 
tested (probing), and the iterative experimenting with new solutions in real environments 
helps the focal firm seize opportunities or new technologies earlier than rivals and prepare for 
threats before they are materialised. Both firms employ an integrated approach to the 3Ps and 
iterate between thinking (perceiving, prospecting) and acting (probing) along the NPD 
process. Integrating happens in every stage, and is particularly peaked in Phase IV, where 
both firms positioned as a lead-operator to organise multiple CSF relationships with partners. 
Notably, learning is intensified in probing practices (experimenting at operational level) 
through actual experience in real environments (learning by doing and real-time foresight), as 
opposed to learning through a mere representation of the environment in perceiving and 
prospecting.  
Overall, a continuous approach rather than a linear sequence supports the view that it 
is the pre-adapted firms which can spot the opportunity earlier than others; namely, their 
capability of sense-making is a higher-order form of experimental learning (Gavetti and 
Levinthal, 2000; Gavetti and Menon, 2016). This implies that successful NPD needs to 
incorporate both forward-looking cognitive intelligence and backward-looking experimental 
wisdom (retrospective sense-making), as well as the co-existence of prospecting and probing 
in Phase III. Therefore, cognitive searching (through perceiving and prospecting) 
complements experimental searching (through probing) to avoid missing opportunities and 
being constrained by a narrow search in a given moment. Mental models, reshaped from 
intensive interaction with new stimuli derived from perceiving and prospecting practices, help 
overcome inertia and bounded rationality, reveal blind spots and enlarge choices of 
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opportunities (Heger and Boman, 2015; Rohrbeck and Gemunden, 2011). Although the 
private firm strove to explore new opportunities for radical changes and the state-owned firm 
aimed to exploit existing resources for incremental innovation (re-innovating existing 
products, e.g. Number Zero), both firms employed exploratory and exploitative skills 
simultaneously in innovation. This is because sensing new opportunities is built on a firm's 
deep understanding of current trends in the industry. Findings show that continuously 
involving CSF practices (3Ps) in innovation processes helps develop a firm’s sensing 
(perceiving weak and strong signals), seizing (iterative prospecting and probing by identifying 
tipping point and strategising) and integrating (probing, learning by doing; reconfiguring) 
aspects of dynamic capabilities. Therefore, CSF can be the antecedent of continuous 
innovation and change and can facilitate the development of organisational ambidexterity 
(Rhisiart et al., 2015).  
  Third, our findings contribute to the open innovation management literature by 
showing that Chinese pharmaceutical firms appropriately managed CSF activities by 
dynamically redefining the foresight boundaries at different stages of NPD to support 
innovation. They started from unstructured CSF practices with loosely-defined personal 
networks at Phases I and II, through intentional (planned and deliberate) contract-based 
relationships at Phase III, moving to intelligent and systematic (purposefully CSF practices), 
lead-operator (dual or triple trajectory) collaboration at Phase IV. First, these CSF methods 
and practices guaranteed that the sources of knowledge synthesised into the foresight process 
was reliable, creative and interactive. Second, it helps develop distinctive foresight 
capabilities (sensing, seizing, integrating) at different stages of NPD respectively. More 
importantly, to a certain extent it offers insights into effective responses to challenges of 
managing intellectual property protection during collaborative innovation (Calof et al., 2018), 
particularly in China, where the institutional environment is not well established. The 
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different governance forms of CSF revealed in this study (loose friendship in Phase I & II, 
contract-based in Phase III and lead operator involving multiple collaboration with 
sub-contractors in Phase IV) largely fill the gap in the literature on how CSF helps overcome 
barriers of open innovation in terms of governance issues at different stages of NPD. This 
supports the claim that the utility of CSF for innovation depends on the strategic management 
of individual firms (Pittaway et al., 2004) and that the choice of CSF form also considers the 
nature of each stage of NPD.  
  Finally, our findings reveal that the ownership structure of a firm could influence its 
choices of CSF practices and the kind of activities it engages in when it comes to manage its 
fleeting futures. The different ownership also means differences in endowed resources, 
organisational context and governing structure, providing contrasting insights which enrich 
our understanding of the role of collaborative foresight in innovation. While the national 
institutional environment in China enabled Statepharma to access financial resources for NPD, 
it constrained Privatepharma which struggled to raise funds for research. Privatepharma was 
more likely to take a long-term and explorative foresight perspective than Statepharma. In 
Privatepharma, engaging CSF was close to a learning process within a broad vision 
(Research-focused), whereas Statepharma paid more attention to results out of CSF practices 
(Development-focused). CSF informed NPD in both firms, but Privatepharma was more 
patient and desired to explore opportunities through learning-by-doing, learning through 
trial-and-error, and also tolerated failure. Seeing investing in basic research as risky, 
Statepharma put efforts into the exploitation of CSF to inform which semi-finished new 
products could be sourced in for profit maximisation. Our study hence contributes to the 
existing literature that the types of ownership, an unexplored factor (e.g. Hojland and 
Rohrbeck, 2018), affects firm’s CSF practices in open innovation for NPD. Future research on 
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SF should bring this factor to the fore, rather than leaving it hidden, or overridden by other 
factors. 
  Therefore, CSF manifested at each stage of NPD was underpinned by various 
organisational theories, such as bounded rationality (cognitive vs experimental search), 
dynamic capability (sensing, seizing, integrating), organisational ambidexterity (managing 
radical and incremental innovation simultaneously). This study hence interconnects 
organisational theories with innovation management. A CSF - 3Ps - open innovation model as 
detailed in Figure 2 builds a foundation for future research.  
-----------Insert Figure 2 here------------ 
6. Conclusion
This study reveals how Chinese pharmaceutical firms leverage collaborative strategic 
foresight practices to support open innovation in stages of NPD. Engaging CSF practices in 
NPD contributes to the development of a firm's sensing, seizing, and integrating foresight 
capabilities, which are important organisational capabilities enabling some firms to 
out-perform others. The nature of CSF in open innovation for NPD revealed in this study and 
the dynamism with which firms refine their foresight boundaries at different stage of NPD 
contribute to knowledge on foresight in innovation. While the management of intellectual 
property is the major challenge in open innovation, especially in developing countries where 
institutional environment is underdeveloped, different governance forms of CSF at different 
stages of NPD revealed in this study have both theoretical and practical implications. The 
interactive and dynamic perspective of strategic foresight overwrites the traditional foresight 
principles, and induces effective strategies in managing innovation. This study therefore 
enhances our understanding of the link between strategic foresight and management of 
innovation, an under-researched area in the existing literature.  
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     Despite our contribution, our study has limitations. Our findings are supported by data 
from two cases. While the purposely selected two cases offer useful and relevant evidence on 
how CSF enables open innovation for NPD in pharmaceutical firms, further research is 
encouraged, to incorporate more cases in order to test our findings in the same or different 
organisational and industrial settings. The long period of drug development means that it is 
challenging to trace the whole NPD process of a new drug. Our findings are drawn from 
interview data from the most appropriate informants who were most knowledgeable about the 
NPD process in the respective firms; the two cases have been in operation over ten years with 
rich experience in drug developments. Further research would benefit from longitudinal data 
collection to track real-time collaborative strategic foresights.  
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Figure1. Collaborative strategic foresight approach to organising open innovation
Figure 2. A conceptual framework of collaborative strategic foresight in NPD 
This article has been accepted for publication in a future issue of this journal, but has not been fully edited. Content may change prior 
to final publication. Citation information: DOI10.1109/TEM.2020.3040041, IEEE Transactions on Engineering Management    
36 
         Table 1. Collaborative strategic foresight practices in the NPD: Phases I and II 
Privatepharma (R-focused NPD) Statepharma (D-focused NPD) 
Objective of NPD 
Identification of opportunities for new ideas and potentialities to reducing NPD uncertainties 
Leading research in HBV liver disease in China 
High speed commercialization of research outputs 
in 3 key areas in China: large infusion, 
cardiovascular medicine, and hypoglycaemic 
medicine 
CSF process Perceiving for new product idea identification 
CSF methods Futures workshops and conferences 
Collaborative partners Doctors and scientists based in universities, research institutes, and hospitals 
Inputs of partners in 
CSF (examples) 
• Different ‘ways of doing’ things, e.g. methods on
improving cancer patients' immune system (which
might be effective in treating liver disease).
• Latest developments on new or similar drugs and
technologies induced in the West e.g. thymic
hormone extracted from cows, white cell hormone
2 on cancer.
• Latest medical research development in the three
key product lines
• Information and suggestions for synthesis of
possible chemical compounds with commercial
potential
CSF contributes to 
innovation  
• Detect signals of change in NPD ahead of competition while interacting with a lot of information
richness across organizational boundaries
• Reduce blind spots and open up to a wider range of innovative opportunities
• Challenge the embedded assumptions, cognitive foundations and limitations and avoid bias about the
future
• Potential to be the first to access to reliable and critical NP information on the research and market front;
enabling to sense opportunities earlier, which is often critical to gain access to scare resources and secure
competitive positions quicker than rivals, e.g. receive new drug samples for cancer in Privatepharma
• Get direct validation of potential next generation of medicines hence to reduce uncertainties
Characteristics of 
CSF 
Be flexible and patient; willing to invest; focused 
(e.g. on liver disease) 
Planned and impatient; unwilling to invest; diverse 
(e.g. any semi-finished drug development with 
commercial potential) 
CSF approaches Explorative Exploitative 
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       Table 2. Collaborative strategic foresight practice in the NPD: Phase III 
Privatepharma (R-focused NPD) Statepharma (D-focused NPD) 
Objective of NPD 
Increase the likelihood of success in NP and protect the NPD 
Tangible NPD on HBV liver disease in China Reduce uncertainties and speed up the NPD 
process 
CSF process Prospecting and probing 
CSF methods Collective exploration and exploitation, collaborative problem solving 
Collaborative partners Doctors at hospitals 
Inputs of partners in 
CSF (examples) 
• Different perspectives, suggestions, and solutions to solving problems at the operational level
• Access to different resources, e.g. doctors with expertise knowledge, patients as trial participants,
physical facilities.
Mobilization of information on opportunities for 
outsourcing in-house research  
In search for information on latest medical 
development 
CSF contributes to 
innovation 
• Intensified interaction with new stimuli reshapes mental models and fosters out-of-box thinking
• Bridge thinking (prospecting) and action (probing) by integrating iterative thoughts trial (prospecting)
and testing (probing) across organisational knowledge boundary, and matching opportunities with
capabilities
• Intensified interaction allows tacit knowledge sharing and creates unique learning opportunities
• Accelerated tacit knowledge accumulation from diverse partners inspires cognitive leaps hence helps
break path-dependency in innovation
Characteristics of CSF A learning cycle between thinking (cognitive) and testing (experimental) 
Pay attention to the process of CSF Pay attention to the results out of CSF practices 
CSF approaches Exploitative Explorative 
Governance of CSF Formal, contract-based 
Foresight  capability 
developed 
Seizing 
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 Table 3.  Collaborative strategic foresight practices in the NPD: Phase IV 
Privatepharma (R-focused NPD) Statepharma (D-focused NPD) 
Objective of NPD Commercializing research output and protection of NP 
CSF process Probing 
CSF methods Competitive intelligence, benchmarking 
Collaborative partners Hospital doctors and experts specializing in different areas; manufacturers in value network 
Inputs of partners in CSF 
(examples) 
Analysis on competitors moves vis a vis the firm's NPD; interpret new technological trajectories 
and trends, to define potential future market demands for next round of NPD 
Mobilizing information on opportunities to 
sourcing in non-core research 
Building up information on latest cutting-edge 
medicine development  
CSF contributes to 
innovation  
• Intensified trial-and-error experiments spanning across industry boundaries enhance interactive
learning and help assess and refine the future insights
• Validating, refining, and real world testing alternative solutions entails self-reviewing and
reconfiguring and embedding the insights into meaningful organisational responses
• Accelerate execution of innovation ideas (probing) through multiple exploitation pathways
Characteristics of CSF Long-term view; innovation capabilities - 
driven 
Short-term perspective; financial profit - driven 
CSF approaches Exploitative Exploitative 
Governance of CSF 
Lead operator; multiple collaboration with sub-contractors 
Triple trajectory: in-house production, 
outsourcing, and source-in non-core research 
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